SERUM COPPER AND ZINC IN TREATED PATIENTS WITH END STAGE RENAL DISEASE

Uremia is a state manifested by impaired kidney function with the consequences of accumulation of harmful toxins and waste products. In end-stage renal disease, atherosclerosis cardiovascular disease is a major cause of morbidity and mortality. In the present studies included the measurement of serum trace elements Zinc (Zn), Cupper (Cu) in (78) patients aged 16-77 year. They were classified into two main groups according to the type of treatment1- End-stage renal disease patients on hemodialysis treatment (n=52, age range 16-76 years).A) Hemodialysis patients with diabetes mellitus (n=20, age range 23-75 years).B) Hemodialysis patients without diabetes mellitus (n=32, age range 16-67 years).2- End-stage renal disease patients on conservative treatment (n=26, age range 20-77 years).The result was compared with those of 25 healthy control groups (age range 16-70 years).The result showed that serum Cu was significantly deceased in patients on hemodialysis treatment but there was a significant increase in patients on conservative treatment. Serum Zn was significantly reduced in all patients studied, however, Cu/Zn ratio was reduced in all chronic renal failure patients on different treatment modalities ;indicating the influence of renal failure and its treatment on Cu/Zn status. In conclusion; chronic renal failure patients on different modalities of treatment experienced altered Cu, Zn status. The different mechanisms underlying these changes are mentioned.